Company Engagement

The Medicines Patent Pool’s work depends on partnerships with stakeholders in the field of HIV, hepatitis C and tuberculosis, and its partnerships with patent holding companies are critical to its success.

Following the November 6 announcement of MPP’s expansion into hepatitis C and tuberculosis treatment approved by its funder UNTAID, the Medicines Patent Pool signed a licensing agreement with Bristol-Myers Squibb (BMS) for hepatitis C medicines daclatasvir (DCV) allowing generic manufacturer to develop and distribute daclatasvir in 112 low- and middle-income countries. 

The MPP has signed licensing agreements with AbbVie, Bristol-Myers Squibb, Gilead Sciences, MSD, Roche, ViiV Healthcare [a joint venture of GlaxoSmithKline, Pfizer and Shionogi], the University of Liverpool and the US National Institutes of Health.

Boehringer-Ingelheim is in negotiations with the Medicines Patent Pool, and Janssen is working alongside the Medicines Patent Pool to support the development of new HIV paediatric treatments through the Paeditric HIV Treatment Initiative (PHTI).

The Medicines Patent Pool has also sub-licensed to generic manufacturers, who are already beginning to produce and supply HIV medicines at a lower cost.  As of November 2015, the MPP had signed sub-licensing agreements with fourteen generic manufacturers: Aurobindo Pharma Limited, Cipla, Desano, Emcure Pharmaceuticals, HEC Pharm, Hetero Labs, Huahai Pharmaceutical, Laurus Labs, Lupin, Micro Labs, Mylan, Shasun Pharma Solutions, Shilpa Medicare and Strides Arcolab.

The MPP looks forward to continuing dialogue with all relevant patent holders and eligible generic manufacturers and product development partnerships in order to achieve the goal of increasing access to medicines for people living with HIV in developing countries.

The table below summarises the current status of engagement with patent holders. The generic manufacturers and product development partnerships are listed in the Sub-licensees page.

Patent Holder Engagement

Patent Holder
AbbVie
Boehringer-Ingelheim
Bristol-Myers Squibb
F. Hoffman-La Roche
Gilead Sciences
Merck Sharp & Dohme (MSD)
Janssen
US National Institutes of Health
ViiV Healthcare
Q4 2015 Q3 2015 Q2 2015 Q1 2015 Q4 2014 Q3 2014 Q2 2014 Q1 2014 Q4 2013 Q3 2013 Q2 2013 Q1 2013 Q4 2012 Q3 2012 Q2 2012 Q1 2012 Q4 2011 Q3 2011 Q2 2011 Q1 2011 Q4 2010
Agreement for adults formulations in Africa signed in December 2015 Agreement for paediatrics
signed in November 2014
Agreement for paediatrics
signed in November 2014
Agreement for paediatrics
signed in November 2014
Agreement for paediatrics signed in November 2014 In negotiations for paediatrics. In negotiations for paediatrics. In negotiations for paediatrics. In negotiations for paediatrics. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Reply received 26 January [pdf]. Sent letter on 1 December [pdf]
In negotiations  In negotiations In negotiations In negotiations In negotiations In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. Not currently in negotiations. Not currently in negotiations. Reply received 19 January [pdf]. Sent letter on 1 December [pdf]
Agreement for daclatasvir signed November 2015 Agreement for atazanavir signed in December 2013  Agreement for atazanavir signed in December 2013 Agreement for atazanavir signed in December 2013 Agreement for atazanavir signed in December 2013 Agreement for atazanavir signed in December 2013 Agreement for atazanavir signed in December 2013 Agreement for atazanavir signed in December 2013 Agreement for atazanavir signed in December 2013 In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. Not currently in negotiations. Not currently in negotiations. Reply received 26 January [pdf]. Sent letter on 1 December [pdf]
Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August 2013 Agreement signed in August In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. Preparing for negotiations. Sent letter on 1 December [pdf]
Licence agreement signed in July 2014.Licence agreement signed in July 2011  Licence agreement signed in July 2014.Licence agreement signed in July 2011 Licence agreement signed in July 2014.Licence agreement signed in July 2011 Licence agreement signed in July 2014.Licence agreement signed in July 2011 Licence agreement signed in July 2014.Licence agreement signed in July 2011 Licence agreement signed in July 2014.Licence agreement signed in July 2011 Licence agreement signed in July 2011. In further negotiations. Licence agreement signed in July 2011. In further negotiations. Licence agreement signed in July 2011.
In further negotiations
Licence agreement signed in July 2011. In further negotiations. Licence agreement signed in July 2011. In negotiations. Licence agreement signed in July 2011. In negotiations. Licence agreement signed in July 2011. Additional amendment made November 2012 [pdf]. In negotiations. Licence agreement signed in July 2011. In negotiations. Licence agreement signed in July 2011. Additional amendments made July 2012 [pdf]. In negotiations. Licence agreement signed in July 2011. In negotiations. Licence agreement signed in July. Amendments made November 2011. In negotiations. Licence agreement signed in July In negotiations. In negotiations. Reply received 14 February [pdf]. Sent letter on 1 December [pdf]
Agreement for paediatrics signed in February 2015 Agreement for paediatrics signed in February 2015  Agreement for paediatrics signed in February 2015 Agreement for paediatrics signed in February 2015 In negotiations. In negotiations. In negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Reply received 28 January [pdf] Sent letter on 1 December [pdf]
Ongoing engagement. Janssen announces expansion of its non-enforcement of IP policy for pediatric darunavir formulations (2015). Ongoing engagement. Janssen announces expansion of its non-enforcement of IP policy for pediatric darunavir formulations (2015). Ongoing engagement. Janssen announces expansion of its non-enforcement of IP policy for pediatric darunavir formulations (2015). Ongoing engagement. Janssen announces expansion of its non-enforcement of IP policy for pediatric darunavir formulations (2015). Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. J&J decision not to licence at this time. Not currently in negotiations. Not currently in negotiations. Not currently in negotiations. Reply Received 31 January [pdf]. Sent letter on 1 December [pdf]
Licence agreement signed in September 2010.  Licence agreement signed in September 2010. Licence agreement signed in September 2010. Licence agreement signed in September 2010. Licence agreement signed in September 2010. Licence agreement signed in September 2010. Licence agreement signed in September 2010. Licence agreement signed in September 2010. Licence agreement signed in September 2010. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010. In negotiations. Licence agreement signed in September 2010
Licence agreement signed in March 2014 for dolutegravir. Licence agreement signed in February 2013 for abacavir. Licence agreement signed in March 2014 for dolutegravir. Licence agreement signed in February 2013 for abacavir. Licence agreement signed in March 2014 for dolutegravir. Licence agreement signed in February 2013 for abacavir. Licence agreement signed in March 2014 for dolutegravir. Licence agreement signed in February 2013 for abacavir. Licence agreement signed in March 2014 for dolutegravir. Licence agreement signed in February 2013 for abacavir. Licence agreement signed in March 2014. Licence agreement signed in March 2014. Licence agreement signed in March 2014. Licence agreement signed in February 2013. In negotiations. Licence agreement signed in February 2013. In negotiations. Licence agreement signed in February 2013. In negotiations. Licence agreement signed in February 2013. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. In negotiations. Sent letter on 1 December [pdf]

 

This page is also available in: French, Spanish